trending Market Intelligence /marketintelligence/en/news-insights/trending/e0YsziFCVi3woURDtp_aUg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

CVS Health launches precision medicine program for cancer patients

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

CVS Health launches precision medicine program for cancer patients

CVS Health Corp. on Dec. 12 launched a precision medicine strategy to help improve outcomes and lower overall costs for cancer patients.

The program called Transform Oncology Care uses genomic testing results at the point-of-prescribing to help determine the best treatment plan for patients based on their clinical and genetic profiles.

CVS Health is offering the plan in partnership with healthcare technology startup Tempus Labs Inc., which offers genomic sequencing and biological modeling services.

The drug retailer said the broad-panel gene sequencing tests help identify a patient's genomic variants and the therapeutic options specific to their molecular and clinical profile. The results of these tests also make it possible for the patient to be part of local clinic trials under Tempus' proprietary platform, facilitating broader access to experimental therapies, CVS Health said.

The program includes company nurse-led care management that is integrated with the payor's existing programs. Payors can also opt for value-based contracts that employ provider networks to improve care and reduce costs, the company said.

CVS Health's Aetna is rolling out the program in 12 states. The company said the program is also available to other health plans.